Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 2.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,350,925 shares of the company's stock after purchasing an additional 38,446 shares during the quarter. Assenagon Asset Management S.A. owned about 2.55% of Stoke Therapeutics worth $14,901,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Quest Partners LLC purchased a new position in Stoke Therapeutics during the second quarter worth about $29,000. Intech Investment Management LLC purchased a new stake in Stoke Therapeutics in the third quarter valued at $160,000. The Manufacturers Life Insurance Company lifted its stake in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock valued at $189,000 after purchasing an additional 1,994 shares during the last quarter. Mesirow Financial Investment Management Inc. acquired a new position in Stoke Therapeutics in the third quarter valued at about $192,000. Finally, Profund Advisors LLC purchased a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at approximately $201,000.

Stoke Therapeutics Price Performance

Shares of STOK stock traded down $0.10 during trading hours on Friday, reaching $9.36. 272,424 shares of the stock were exchanged, compared to its average volume of 672,022. Stoke Therapeutics, Inc. has a 12-month low of $4.09 and a 12-month high of $17.58. The business's fifty day moving average is $11.49 and its two-hundred day moving average is $12.89. The firm has a market capitalization of $495.80 million, a P/E ratio of -4.46 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on STOK shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. Finally, Leerink Partners began coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an "outperform" rating and a $18.00 price target on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of "Buy" and a consensus target price of $21.29.

Insider Buying and Selling at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the sale, the general counsel now directly owns 35,142 shares in the company, valued at $449,114.76. This trade represents a 21.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barry Ticho sold 13,945 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the sale, the insider now owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock worth $809,421 over the last ninety days. Corporate insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.